CAMBRIDGE, England--(BUSINESS WIRE)--Avacta Group plc (AIM:AVCT), the developer of Affimer ® biotherapeutics and reagents, is pleased to provide an update on the Affimer therapeutics development ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results